UBS Group
ADPT icon

UBS Group’s Adaptive Biotechnologies ADPT Stock Holding History

UBS Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4M Buy
+2,862,120
New +$43.9M 0.01% 1540

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS Group's ADPT Position: Q2 2026 in Review

UBS Group increased its Adaptive Biotechnologies (ADPT) stake by 19% in Q2 2026, buying an estimated $650K and bringing the position to 268,439 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4023.

UBS Group first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.31M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • UBS Group held 268,439 shares of Adaptive Biotechnologies worth $5.76M as of Q2 2026.
  • UBS Group bought 42,453 Adaptive Biotechnologies shares in Q2 2026, an estimated $650K.
  • Adaptive Biotechnologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4023 holding.
  • UBS Group first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • UBS Group's Adaptive Biotechnologies position peaked at $8.31M in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.